$IRTC

iRhythm Holdings, Inc. (IRTC) Details Data Exfiltration, Starts Notifications

iRhythm Holdings (IRTC) reported data exfiltration in third-party apps from June 3-8, 2026, affecting patient and insurance data. The company began notifying impacted individuals and stated no material financial impact is expected. This follows a previous breach disclosure in June 2026.

Original reporting
Published Oct 2, 2026, 8:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 2, 2026, 9:01 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
iRhythm Holdings, Inc. (IRTC) Details Data Exfiltration, Starts Notifications — source image
Decision brief

The 30-second read

$IRTCBearishLow
01

Why it matters

The breach could trigger regulatory inquiries and class-action lawsuits, increasing legal expenses and affecting investor confidence.

02

Market read

First report of a data breach at iRhythm, likely to cause short‑term downside pressure.

03

What to watch

Potential insurance reimbursements for breach response costs are not disclosed.

Relevance 5/10Novelty 7/10Timing: today

Background

iRhythm is a US‑listed digital health company providing cardiac monitoring solutions.

Company-level read

Ticker impact

$IRTCBearishMedium confidence
Context

iRhythm disclosed a data exfiltration affecting patient identifiers and insurance numbers, the first public report of the breach.

Expected impact

likely downside as market prices in potential remediation and legal expenses

Evidence & confidence

First disclosure of a breach typically triggers short-term sell pressure, especially for a health‑tech firm with sensitive data.

Market effects

May raise concerns for other digital health companies about data security standards.

US health‑tech sector could see modest pullback.

Limited to investors tracking cybersecurity risk in healthcare.

Counterpoint

If the breach is contained with minimal financial impact, the stock could rebound quickly.

Key entities

  • iRhythm Holdings, Inc.

    Subject of the data breach disclosure.

Related articles

MedAI 8/10

iRhythm Completes VitalConnect Acquisition

iRhythm Technologies acquired VitalConnect for $287.5M, combining cardiac monitoring technologies. The deal includes $237.5M in cash, 423,334 shares, and $10M in interim capital. VitalConnect's revenue was $65M in 2026. iRhythm aims to boost growth and maintain a 15% EBITDA margin in 2027, with updated guidance expected in Q3 2026 earnings.

$IRTCMedAI 8/10

iRhythm completes acquisition of VitalConnect

iRhythm (IRTC) completed its acquisition of VitalConnect for $237.5M in cash and up to 423,334 shares. The deal includes a $10M working capital funding. VitalConnect's cardiac monitoring platform offers 30-day patient monitoring and 11 physiological parameters. iRhythm expects enhanced revenue growth from 2027, maintaining a 15% adjusted EBITDA margin target. Updated 2026 guidance will be provided in November 2026.

$IRTCMedAI 9/10

Transaction Detail The purchase consideration consisted of $237.5 million in cash, subject to customary adjustments, funded from iRhythm's balance sheet and…

iRhythm Holdings, Inc. (IRTC) filed an SEC Form 8-K — Regulation FD Disclosure. iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care  Combination broadens iRhythm’s cardiac monitoring portfolio, advances its multi-vitals strategy and expands iRhythm’s addressable mark

$IRTCHighAI 9/10

iRhythm Completes Acquisition of VitalConnect, Expanding Its Cardiac Monitoring Platform Across Ambulatory, Inpatient and Hospital-to-Home Care

iRhythm (IRTC) completed its acquisition of VitalConnect, a leader in wearable biosensor and ambulatory cardiac monitoring technology. The $237.5M cash deal, plus up to 423,334 shares, is expected to expand iRhythm's cardiac monitoring portfolio, accelerate growth, and preserve its 15% adjusted EBITDA margin target for 2027. The combined entity aims to serve more patients and customers across various care settings.